A Randomized, Double-Blind, Placebo-Controlled, Phase II Study Assessing Safety, Tolerability, and Efficacy of Bryostatin in the Treatment of Moderately Severe to Severe Alzheimer’s Disease

BACKGROUND: Bryostatin-activated PKC epsilon pre-clinically induces synaptogenesis, anti-apoptosis, anti-amyloid-β oligomers, and anti-hyperphosphorylated tau. OBJECTIVES: To investigate bryostatin safety, tolerability, and efficacy to improve cognition in advanced Alzheimer’s disease (AD) patients....

Descripción completa

Detalles Bibliográficos
Autores principales: Farlow, Martin R., Thompson, Richard E., Wei, Lee-Jen, Tuchman, Alan J., Grenier, Elaine, Crockford, David, Wilke, Susanne, Benison, Jeffrey, Alkon, Daniel L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: IOS Press 2019
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6398557/
https://www.ncbi.nlm.nih.gov/pubmed/30530975
http://dx.doi.org/10.3233/JAD-180759

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6398557/
https://www.ncbi.nlm.nih.gov/pubmed/30530975
http://dx.doi.org/10.3233/JAD-180759

Ejemplares similares